dc.contributor.advisor |
Ferrier, R J |
|
dc.contributor.author |
Erasmuson, Anton Francis |
|
dc.date.accessioned |
2008-12-18T20:49:17Z |
|
dc.date.available |
2008-12-18T20:49:17Z |
|
dc.date.copyright |
1976 |
|
dc.date.issued |
1976 |
|
dc.identifier.uri |
http://researcharchive.vuw.ac.nz/handle/10063/736 |
|
dc.description.abstract |
In a program aimed at developing a chemically derived vaccine against sporidesmin-A, the toxin which causes the pasture disease facial eczema, two haptens have been prepared, coupled to protein carriers, and tested for immunogenicity. The hapten, 2-amino-5-chloro-3,4-dimethoxybenzyl alcohol has been synthesised from vanillin and the general synthetic methods developed in the course of this work have been used to prepare a large number of related vanillin derivatives for use in cross-hapten studies. The carbon-13 nuclear magnetic resonance spectra of 16 vanillin derivatives have been obtained, and two independent methods of deducing vanillin substitution patterns have been developed. 5-chloro-6, 7-dimethoxy-N-methyl-lH-indole has been prepared by a new route and its 3-oxoacetic acid derivative has been synthesized for use as a hapten. The Vilsmeier-Haack intermediate, l-methyl-3-(N,N-dimethylimonio) methyl-lH-indole chloride was isolated and a number of possible synthetic routes from it to pyrroloindoles were explored. The vanillin and indole haptens have been coupled to protein carriers to form antigens which generated a low antibody response. However, the use of mycobacterium phlei as a carrier greatly increased the antibody response but the antibodies produced did not interact strongly with sporidesmin-A. |
en_NZ |
dc.language.iso |
en_NZ |
|
dc.publisher |
Victoria University of Wellington |
en_NZ |
dc.subject |
Antigens and antibodies |
en_NZ |
dc.subject |
Medical chemistry |
en_NZ |
dc.subject |
Sporidesmin |
en_NZ |
dc.subject |
Haptens |
en_NZ |
dc.subject |
Facial eczema |
en_NZ |
dc.subject |
Pithecayces chartarum |
en_NZ |
dc.title |
Synthesis of Sporidesmin Based Antigens |
en_NZ |
dc.type |
Text |
en_NZ |
vuwschema.contributor.unit |
School of Chemical and Physical Sciences |
en_NZ |
vuwschema.subject.marsden |
320299 Immunology |
en_NZ |
vuwschema.subject.marsden |
250406 Immunological and Bioassay Methods |
en_NZ |
vuwschema.subject.marsden |
320305 Medical Biochemistry: Proteins and Peptides |
en_NZ |
vuwschema.type.vuw |
Awarded Doctoral Thesis |
en_NZ |
thesis.degree.discipline |
Chemistry |
en_NZ |
thesis.degree.grantor |
Victoria University of Wellington |
en_NZ |
thesis.degree.level |
Doctoral |
en_NZ |
thesis.degree.name |
Doctor of Philosophy |
en_NZ |
vuwschema.subject.anzsrcfor |
119999 Medical and Health Sciences not elsewhere classified |
en_NZ |